606 results about "Lipid Body" patented technology

The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

This invention relates to in-situ preparation of the derivatives of various hydroxy acids (HA), such as alpha-(Alpha) Hydroxy Acids (AHA), beta-(Beta) Hydroxy Acids (BHA), and Poly-Hydroxy Acids (PHA) with certain skin beneficial organic hetero-atom bases and their application in skin resurfacing (exfoliation), and in the synergistic treatment and regulation of topical disorders of skin such as skin aging, wrinkles, acne, rosacea, age-spots, canker sores, striae distensae (stretch marks), pimples, skin redness, and dry skin conditions of cracking, flaking, and scaling. Most HA derivatives produced by the in-situ method do not cause skin irritation and skin redness effects that are commonly experienced with AHA and BHA, yet there is no loss of their skin beneficial effects. These compositions can be traditional water and oil emulsions, liposomes, suspensions, colloids, solutions, masks, muds, serums, sprays, gels, lotions, creams, cleansers, and anhydrous systems, thus offering a wide choice of formulations to meet their consumer appeal and acceptance requirements.

The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage.

Personal care and hygiene formulations for topical application to mucosal surfaces. These formulations include an amphiphilic lipid carrier in the form of a colloidal composition which can include a micellar aggregate or mixed micelles dispersed in a continuous aqueous phase, or an emulsion of lipid droplets suspended in a continuous aqueous phase, and an active agent which is an anti-microbial agent. The lipid carrier has high adhesiveness to mucous membranes such as the soft tissues of the oral cavity. The lipid carrier also has a high load capacity for the active agent to be carried to these tissues. These formulations have the desirable properties of carrying a large amount of active agent for controlled and prolonged release thereof at the desired site, such as mucous membrane surfaces and surrounding tissue. Accordingly, the present invention provides a formulation for oral or topical application including an anti-microbial agent and a lipid. The agent is held by the carrier through a hydrophobic interaction and is released from the carrier in a controlled manner over a prolonged period of time. The lipid is also characterized by having a high adhesive capability towards mucous membrane surfaces. The lipid and the agent are preferably present in a ratio in a range of from about 1:10 to 10:1, more preferably from about 1:5 to about 5:1, and most preferably from about 1:3 to about 3:1 in the formulation.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

The present invention relates to compositions and methods for intracellular protein delivery. The compositions include a protein operatively associated with a cationic lipid in such a way as to facilitate intracellular delivery of the protein by the cationic lipid, such as by associating directly with a cationic lipid, encapsulating it in a cationic liposome, associating the protein with a lipoplex comprising cationic lipid and nucleic acid, or associating the protein with an anionic polymer that is in association with a cationic lipid. These compositions are useful in delivering antibodies to intracellular proteins to neutralize their activity, and to introduce therapeutically useful proteins, peptides or small molecules.

The invention belongs to the field of biological analysis and detection and relates to fluorescent probes for labelling and / or detecting lipid droplets in cells as well as preparation and applicationsof the fluorescent probes. The probes are synthesized with 4-bromo-1,8-naphthalic anhydride as an initial material and take 1,8-naphthalimide as a fluorophore, a C12 alkyl long chain as a specific lipid droplet positioning group and an N-containing group on the 4th site of a naphthalene ring as a fluorescence enhanced and stabilized group. The probes are simple to prepare and have high yield. Compared with existing Nile red and boron dipyrromethene lipid droplet fluorescent probes, the probes have high light stability and large stokes shift and are more suitable for fluorescence imaging. Theprobes have very important application value in cell labelling fluorescent imaging and biomedical fields.

Exemplary embodiments of the present disclosure include a combined catheter-based optical coherence tomography-two-photon luminescence (OCT-TPL) imaging system. Exemplary embodiments further include methods to detect, and further characterize the distribution of cellular components (e.g., macrophage, collagen / elastin fiber, lipid droplet) in thin-cap fibroatheromas with high spatial resolution in vivo.

The invention provides a ratio type fluorescent probe for distinguishing lipid droplets with different polarities. A chemical name is (E)-7-(N,N-diethylamino)-3-(3-(4-(diphenylamine)phenyl)acrylyl-2H-benzopyrone; N,N-diethylamino salicylic aldehyde reacts with ethyl acetoacetate to generate 3-acetyl-7-(diethylamino)coumarin; the product reacts with 4-(N,N-Diphenylamino)benzaldehyde (4) to obtain the fluorescent probe. The fluorescent probe has a two-photon property and an aggregation-induced light-emitting property; a whole body of the probe is electrically neutral and can be positioned in thelipid droplets with the different polarities very well. The probe has low toxicity, good optical stability and specific response on the polarities; detection on the polarities of the lipid droletps in organs and living bodies is realized. The invention further provides a synthesis method of the probe; the synthesis method has the advantages of simple steps, convenient for purification and high yield.

Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and / or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye in an amount and for a duration sufficient to reduce ocular neovascularization. According to the invention the formulations are preferably in pharmaceutically acceptable formulations for topical ocular application, ocular injection, or ocular implantation, and may be contained in liposomes or slow release capsules.

The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.

The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as insulin, is conjugated directly to the polymer. Lipids in the particle are selected to further stabilize the composition during fabrication and digestion, providing sustained delivery of the biologic with native activity. Methods of making and using the invention compositions to administer the biologic agent in vivo are also included.

The present invention relates to compositions and methods for intracellular protein delivery. The compositions include a protein operatively associated with a cationic lipid in such a way as to facilitate intracellular delivery of the protein by the cationic lipid, such as by associating directly with a cationic lipid, encapsulating it in a cationic liposome, associating the protein with a lipoplex comprising cationic lipid and nucleic acid, or associating the protein with an anionic polymer that is in association with a cationic lipid. These compositions are useful in delivering antibodies to intracellular proteins to neutralize their activity, and to introduce therapeutically useful proteins, peptides or small molecules.

The invention relates to preparation and an application of a biodegradable thermosensitive in-situ hydrogel. The hydrogel is prepared by the following steps: by taking a water soluble amphiphilic thermosensitive block polymer polybutyrolactone lactide-polyethylene glycol-polymer polybutyrolactone lactide as a carrier material, dispersing or dissolving the medicine in aqueous liquor thereof; or dispersing particles such microballoon, lipidosome and emulsion droplets which load the medicine in the aqueous liquor. When the temperature is lower than the phase inversion temperature, the hydrogel exists in form of a liquid which can be delivered by way of injection and the like. When temperature at the delivery part is raised to body temperature, the hydrogel gelates and the medicine is slowly released by way of diffusion or / and corrosion, and the release rate of the medicine can be adjusted by changing concentration, molecular weight, proportion of hydrophilic blocks and hydrophobic blocks or block constitution of the polymer. The hydrogel can be delivered by way of eyes, transdermal delivery, vagina, urethra, rectum, nasal cavity and ears.

SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes. The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN38 into complexes and are capable of solubilizing relatively high concentrations of SN38.

The invention discloses an amphiphilic lipid-droplet fluorescent probe with super-high selectivity. The amphiphilic lipid-droplet fluorescent probe with super-high selectivity is characterized in that chemical name of the probe is 1-(3'-(7'-nitrobenzofurazan-4'-)aminopropyl)-2,3,3-trimethylindole bromine, NII for short; and the general chemical formula is as shown in the formula (I). The invention also discloses application of the probe in specifically marking or displaying the form and distribution of lipid droplets in living cells or tissues. Experiments confirm that the probe of the invention is a brand-new probe, has a wide range of application, has good single- and two-photon photostability, fast staining speed and low cytotoxicity, can specifically image lipid droplets in living cells and has a wide application prospect.

The invention relates to a novel preparation method of anthocyanin lipidosome, which solves the problems of poor stability and low bioavailability of free anthocyanin. Based on the characteristic that the stability of anthocyanin is greatly affected by pH, the method adopts the combination of pH gradient and reverse evaporation to obtain anthocyanin lipidosome suspension, and then the anthocyanin lipidosome suspension is subjected to membrane extrusion or circular high-pressure homogenization to obtain the anthocyanin lipidosome with different particle size ranges. As the anthocyanin lipidosome suspension is difficult to store, a freeze-drying protective additive is added during preparation of the lipidosome to pre-freeze the suspension at -65 DEG C and then to freeze and dry the suspension in a freezer dryer, so that freeze-dried anthocyanin lipidosome powder is obtained. The anthocyanin lipidosome prepared by the method has a high embedding rate reaching up to 85.88%, the lipidosome within a particle size range from 100nm to 234nm can be obtained by different processing methods, and the embedding rate of the lipidosome after freeze-drying and redissolving can reach 82.5%. The anthocyanin is improved in in-vivo stability and bioavailability after being embedded by the lipidosome.

The invention relates to an anti-tumor targted lipidosome decorated by pH sensitive polypeptide. The lipidosome is mainly prepared by phospholipid, cholesterol, lipid-polyethylene glycol and lipid-polyethylene glycol-pH sensitive polypeptide. The pH sensitive polypeptide can have enhanced transmembrane capacity in an acidified environment of tumor tissue, and the lipidosome can be mediated to efficiently enter a cell on a tumor part.

The invention discloses a compound with an aggregation induced luminescence property and a preparation method and application thereof in lipid droplet targeting light activating fluorescence imaging. The structure of the compound and the structure of an intermediate product of the compound are represented as the formula I and the formula II, and the formula I can be converted to generate the formula II under the light condition. The compound in the formula I is prepared through the following steps that a compound in the formula III and a compound in the formula IV are dissolved in acetonitrile under the protection of nitrogen, light avoiding reaction is conducted, and the 1,2-dihydro-2-diphenyleneimine ketone compound in the formula I is generated. The novel compound with the aggregation induced luminescence property has the aggregation induced luminescence advantage and can effectively overcome the aggregation induced quenching defect of traditional fluorescent dye, and thus lipid droplet targeting specificity light activating fluorescence imaging in a living cell can be achieved; in addition, the compound has the advantages that the light activating efficiency and the signal-to-noise ratio are high, the cytotoxicity is small, the Stokes shift is large, and the capability of the compound to enter cells is high; and cancer cells and normal cells can be effectively distinguished.

The invention discloses a lipidosome encapsulating epigallocatechin gallate and a preparation method process. The lipidosome consists of the following components: soya bean lecithin, cholesterol, epigallocatechin gallate, buffer liquor and tween-80. The preparation method disclosed by the invention is simple in process and the EGCG lipidosome is prepared by a reverse evaporation method, and ultrasonic treatment is carried out on the lipidosome by a water bath ultrasonic instrument till the system is stable. The method can remarkably improve the stability of the EGCG lipidosome, and the grain size of the lipidosome can be effectively controlled and the encapsulation efficiency can be effectively improved by adjusting the ratio of the lipid components and the buffer liquor through the technical steps such as magnetic stirring, ultrasonic treatment and rotary evaporation. The EGCG lipidosome disclosed by the invention develops the application range of lipidosome, and the lipidosome is used as a carrier to encapsulate EGCG, so that the lipidosome is simple in preparation process, lower in demand on equipment, convenient to popularize and apply and can be industrially produced.

The invention discloses a novel lipid material. The novel lipid material is used for prolonging the circulating time and increasing the transfer amount of medicine to brain tumor tissues in a target way. The novel lipid material is characterized in that polyethylene glycol is used as a bridge, one side of the bridge is connected with cholesterol, and one side of the bridge is connected with glucose and RGD (arginine-glycine-aspartic acid) peptide, so that the lack of brain tumor targeting ability by the lipid modified by the single glucose or the RGD peptide is overcome, and the brain tumor can be effectively targeted after blood brain barrier crossing. The novel lipid material can be used for different preparation types of lipids, nanoparticles, micelles and the like; the prepared paclitaxel-carrying lipid has obvious brain tumor targeting function, and broad application prospect.

The invention discloses a cell lipid droplet specific-labeling fluorescent probe. The fluorescent probe has a chemical name of 1-(3'-(7'-nitrobenzofuran-4'-)aminopropyl)-4-methylpyridine bromide and has a general chemical formula shown in the formula (I). The invention also discloses a use of the fluorescent probe in specific labeling or display of a lipid droplet form and distribution in living cells. An experiment result shows that the cell lipid droplet specific-labeling fluorescent probe has the characteristics of very high selectivity, background noise-free imaging, two-photon performances, very good light stability, fast dyeing ability, no use of washing and low cytotoxicity and has a great application prospect.

This invention belongs to chemistry pharmaceutical field and relates to a medication transfer system, especially relates to an agglutinin masked medication-load transfer mechanism transferring from nose to brain. This invention comprises medication carrier nanograin, vesicle or lipid body surface finish agglutinin. By using the transfer system, resort time of medication-load system on nasal mucosa can be prolonged, dielectric mucosa absorb the medication-load system and selectively deliver small molecular chemistry medication, diagnosis medication, polypeptide proteins and gene medication into brain. This invention can deliver more medication into brain and relatively decrease medication in outer tissue, so it can depress toxic action at every pore while toning up prevention, cure and diagnosis effect of backbone diseases.

The invention discloses a conjugate of fatty aminoacyl alexan, preparation and application in anti-tumor thereof. The invention also discloses a pharmacosome of the conjugate of fatty aminoacyl alexan, preparation thereof, and its applicant in anti-tumor and preparation of target medicine material of microemulsion, lipid medicine carrier. In comparison with alexan, the inventive conjugate of fatty aminoacyl alexan has a strong transmembrane ability, high bioavailability, long halflife, and amphipathic nature. It is demonstrated that the inventive compound and pharmacosome have great anti-tumor activity.

The invention discloses a method for preparing peanut antioxidant peptide by fermentation, and the method comprises the following steps: adding distilled water to low-denatured degreased peanut protein powder, ultrasonically dispersing and dissolving, adjusting the pH value, sterilizing and cooling; inoculating with strain seed culture liquid, and fermenting and culturing; and carrying out ultrasonic-assisted enzymolysis, inactivating enzyme, centrifuging, and freeze-drying supernatant to obtain the peanut antioxidant peptide. The peanut antioxidant peptide prepared by the method disclosed by the invention has the antioxidant activities of scavenging hydroxyl free radical, superoxide anion free radical and DPPH (1,1-diphenyl-2-picrylhydrazyl) free radical, inhibiting hydroxyl-free-radical-mediated deoxyribose injury, inhibiting peroxidation of lipidosome, resisting oxidation of linolic acid system, resisting grease peroxidation capability and the like, and has iron reduction capability, molybdenum reduction capability, iron ion chelating capability and copper ion chelating capability; and the method is simple to operate, has mild reaction conditions and is suitable for industrial production.

The invention discloses a protein-polysaccharide glass slow releasing microball preparing method of low-temperature water phase-water phase emulsion, which comprises the following steps: allocating water-phase-water-phase emulsion; freezing the emulsion; freeze-drying the sample to obtain the protein-polysaccharide glass; dispersing the micro-particle of protein-polysaccharide in the primary emulsion of oil-soluble macromolecular solution; forming water-in-oil in the water-phase; or forming primary emulsion to decompose macromolecular solution; spraying to dry; adding addictive in the gel; fitting for peptide, antibody or grease body agent.

The invention belongs to the field of medicament preparations, and discloses an octreotide acetate lipidosome precursor and a preparation method thereof. The precursor lipidosome contains octreotide acetate, negatively-charged phospholipid and a cryoprotectant, and can contain an appropriate quantity of other lipids including phosphatidylchline and cholesterol; components such as an antioxidant, a pH regulating agent and the like can be added as required; the molar ratio of the octreotide acetate to the negatively-charged phospholipid is smaller than 1:1; and the mass ratio of the negatively-charged phospholipid to the cryoprotectant is 1:1-1:10. In the invention, a tert-butyl alcohol-water cosolvent freeze-drying method is adopted. The entrapment rate of an octreotide acetate lipidosome / micelle obtained by hydrating a freeze-dried product can be over 50 percent, an octreotide acetate lipidosome / micelle obtained by hydrating the freeze-dried product has high stability, and the problem of difficulty in entrapping a protein polypeptide medicament during preparation of a lipidosome / micelle preparation is solved. The preparation method is simple and practicable, and is suitable for industrial mass production.